Nifuroxazide mitigates cholestatic liver injury by synergistic inhibition of Il-6/Β-catenin signaling and enhancement of BSEP and MDRP2 expression

•NIF successfully reversed cholestasis to a similar extent compared to the mainstay drug, ursodeoxycholic acid.•NIF successfully mitigated cholestasis through synergistic inhibition of Il-6/Β-catenin pathways.•NIF directly enhanced the hepatic expression of bile acids transporters genes.•Molecular d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2021-10, Vol.99, p.107931, Article 107931
Hauptverfasser:	Nazmy, Entsar A., Helal, Manar G., Said, Eman
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Attenuation Bile Bile acids Binding sites BSEP Cell differentiation Cholestasis Diarrhea Gallbladder diseases Gene expression Hepatocytes Histochemical analysis Homeostasis Il-6 Inflammation Inflammatory response Injuries Interleukin 6 Liver MDRP2 Molecular docking Multidrug resistance Nifuroxazide Proliferating cell nuclear antigen Proteins Strong interactions (field theory) Ursodeoxycholic acid Β-catenin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!